KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Total Non-Current Liabilities: 2018-2025

Historic Total Non-Current Liabilities for Castle Biosciences (CSTL) over the last 2 years, with Sep 2025 value amounting to $94.2 million.

  • Castle Biosciences' Total Non-Current Liabilities was N/A to $94.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $94.2 million, marking a year-over-year change of. This contributed to the annual value of $62.0 million for FY2023, which is 29.02% up from last year.
  • Castle Biosciences' Total Non-Current Liabilities amounted to $94.2 million in Q3 2025, which was up 7.27% from $87.9 million recorded in Q2 2025.
  • Castle Biosciences' Total Non-Current Liabilities' 5-year high stood at $94.2 million during Q3 2025, with a 5-year trough of $32.5 million in Q4 2021.
  • For the 3-year period, Castle Biosciences' Total Non-Current Liabilities averaged around $62.7 million, with its median value being $56.0 million (2024).
  • As far as peak fluctuations go, Castle Biosciences' Total Non-Current Liabilities skyrocketed by 47.76% in 2022, and later declined by 11.28% in 2023.
  • Quarterly analysis of 5 years shows Castle Biosciences' Total Non-Current Liabilities stood at $32.5 million in 2021, then soared by 47.76% to $48.1 million in 2022, then rose by 29.02% to $62.0 million in 2023, then surged by 34.40% to $56.0 million in 2024, then reached $94.2 million in 2025.
  • Its Total Non-Current Liabilities stands at $94.2 million for Q3 2025, versus $87.9 million for Q2 2025 and $56.0 million for Q1 2024.